A Study of ARRY-142886 in Patients With Advanced Cancer
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study during which patients with advanced solid tumors will receive
investigational study drug ARRY-142886.
This study has 2 parts. In the first part, patients will receive increasing doses of study
drug in order to achieve the highest dose of study drug possible that will not cause
unacceptable side effects. Approximately 25 patients from the US will be enrolled in Part 1
(Completed).
In the second part of the study, patients will receive the best dose of study drug,
determined from the first part of the study, and will be followed to see what side effects
the study drug causes and what effectiveness the study drug has, if any, in treating the
cancer. Approximately 35 patients from the US will be enrolled in Part 2 (Completed).
Phase:
Phase 1
Details
Lead Sponsor:
Array BioPharma Array Biopharma, now a wholly owned subsidiary of Pfizer